Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Leerink Partnrs decreased their Q2 2025 EPS estimates for Regeneron Pharmaceuticals in a research note issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $6.97 for the quarter, down from their prior forecast of $7.71. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 EPS. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year.
Other analysts have also recently issued reports about the stock. Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price for the company. in a report on Friday, May 30th. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research note on Monday, June 2nd. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Finally, The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $823.54.
View Our Latest Report on REGN
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ REGN traded up $7.98 during mid-day trading on Wednesday, reaching $567.74. 844,285 shares of the company traded hands, compared to its average volume of 913,803. The firm has a market cap of $61.30 billion, a PE ratio of 14.45, a price-to-earnings-growth ratio of 2.06 and a beta of 0.33. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock has a fifty day simple moving average of $545.98 and a 200-day simple moving average of $621.52.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares in the last quarter. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Finally, Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $27,000. Institutional investors own 83.31% of the company's stock.
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
